Evolus Inc (EOLS)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
David Moatazedi
Employees:
170
520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH, CA 92660
(949) 284-4555

Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. Jeuveau is a proprietary 900 kilodalton purified botulinum toxin type A formulation for the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Data derived from most recent annual or quarterly report
Market Cap 571.7 Million Shares Outstanding56.049 Million Avg 30-day Volume 496.47 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.34
Price to Revenue4.9131 Debt to Equity1.5267 EBITDA-69.845 Million
Price to Book Value13.882 Operating Margin-55.8393 Enterprise Value637.584 Million
Current Ratio2.599 EPS Growth0.596 Quick Ratio2.048
1 Yr BETA 1.1279 52-week High/Low 14.34 / 5.06 Profit Margin-59.3497
Operating Cash Flow Growth-1122.9324 Altman Z-Score-0.7822 Free Cash Flow to Firm -91.627 Million
Earnings Report2022-11-02
View SEC Filings from EOLS instead.

View recent insider trading info

Evolus Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding EOLS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding EOLS

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2022-09-08 by BLANK SIMONE
  • 4: filed on 2022-09-06 by FARRELL PETER C
  • 4: filed on 2022-09-06 by BEAVER SANDRA
  • 3: filed on 2022-09-06 by BEAVER SANDRA
  • 4: filed on 2022-08-03 by MEDYTOX INC.
  • 4: filed on 2022-05-18 by MOATAZEDI DAVID
  • 4: filed on 2022-05-18 by SILVERNAIL LAUREN P
  • 4: filed on 2022-05-17 by GILL DAVID N
  • 4: filed on 2022-03-30 by MOATAZEDI DAVID
  • 4: filed on 2022-03-10 by MUILENBURG CRYSTAL

    • Events (8k)

  • 8-K: filed on 2022-08-30:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-10:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-04:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-26:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-05:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2021-12-14:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    30 Thousand total shares from 2 transactions

    Open Market Sells (S)

    26 Thousand total shares from 1 transactions

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    FARRELL PETER C

    • Director
    		 44,881 2022-09-06 2

    BLANK SIMONE

    • Director
    		 422,458 2022-09-06 2

    BEAVER SANDRA CHIEF FINANCIAL OFFICER

    • Officer
    		 205,601 2022-09-05 2

    MEDYTOX INC.

    • 10% Owner
    		 7,437,652 2022-08-01 1

    SILVERNAIL LAUREN P SEE REMARKS

    • Officer
    		 141,571 2022-05-17 3

    MOATAZEDI DAVID SEE REMARKS

    • Officer
    • Director
    		 491,961 2022-05-16 4

    GILL DAVID N

    • Director
    		 29,568 2022-05-13 2

    AVELAR RUI SEE REMARKS

    • Officer
    		 253,189 2022-03-08 2

    MUILENBURG CRYSTAL CHIEF MARKETING OFFICER

    • Officer
    		 134,248 2022-03-08 2

    HAYMAN ROBERT

    • Director
    		 57,608 2022-01-24 1

    PARSCHAUER KARAH HERDMAN

    • Director
    		 57,608 2022-01-24 1

    MALIK VIKRAM

    • Director
    		 92,019 2022-01-24 1

    STEWART BRADY

    • Director
    		 36,508 2022-01-05 2

    ALPHAEON 1 LLC

    		6,064,871 2021-09-02 0

    JAFAR MICHAEL M. SEE REMARKS

    • Officer
    		 219,851 2021-01-27 0

    ROMINE KRISTINE

    • Director
    		 0 2020-01-23 0

    HAU BOSUN

    • Director
    		 0 2020-01-23 0

    AEON BIOPHARMA, INC.

    • FORMER 10% OWNER
    		 No longer subject to file 2020-01-08 0

    GILL DAVID N

    GILL DAVID N

    • Director
    		 0 2019-01-23 2

    SILVERNAIL LAUREN P SEE REMARKS

    SILVERNAIL LAUREN P SEE REMARKS

    • Officer
    		 0 2019-01-23 3

    MARMO J CHRISTOPHER CHIEF OPERATING OFFICER

    • Officer
    		 0 2018-02-07 0

    SIMHAMBHATLA MURTHY V SEE REMARKS

    • Officer
    • Director
    		 100,224 2018-02-07 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    FARRELL PETER C - Director by trust

    		2022-09-06 20:03:30 -0400 2022-09-06 P 10,000 $9.10 a 10,000 indirect

    BLANK SIMONE - Director

    		2022-09-08 09:29:12 -0400 2022-09-06 P 20,000 $9.24 a 54,881 direct

    BEAVER SANDRA - Officer CHIEF FINANCIAL OFFICER

    		2022-09-06 17:08:50 -0400 2022-09-05 A 36,443 a 36,443 direct

    BEAVER SANDRA - Officer CHIEF FINANCIAL OFFICER

    		2022-09-06 17:08:50 -0400 2022-09-05 A 169,158 a 169,158 direct

    MEDYTOX INC. - > 10% Owner

    		2022-08-03 16:08:17 -0400 2022-08-01 S 26,000 $13.28 d 7,437,652 direct -1.2605 -1.8908 1.7857 3 -5.9874 4

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    EVOLUS INC EOLS 2022-09-08 15:15:04 UTC 2.013 0.307 500000
    EVOLUS INC EOLS 2022-09-08 14:45:03 UTC 2.013 0.307 500000
    EVOLUS INC EOLS 2022-09-08 14:15:03 UTC 2.013 0.307 500000
    EVOLUS INC EOLS 2022-09-08 13:45:03 UTC 2.0219 0.2981 500000
    EVOLUS INC EOLS 2022-09-08 13:15:03 UTC 2.0219 0.2981 500000
    EVOLUS INC EOLS 2022-09-08 12:45:03 UTC 2.0219 0.2981 500000
    EVOLUS INC EOLS 2022-09-07 22:15:05 UTC 2.0219 0.2981 500000
    EVOLUS INC EOLS 2022-09-07 21:45:05 UTC 2.0219 0.2981 500000
    EVOLUS INC EOLS 2022-09-07 21:15:04 UTC 2.0219 0.2981 500000
    EVOLUS INC EOLS 2022-09-07 20:45:03 UTC 2.0215 0.2985 500000
    EVOLUS INC EOLS 2022-09-07 20:15:05 UTC 2.0215 0.2985 500000
    EVOLUS INC EOLS 2022-09-07 19:45:04 UTC 2.0215 0.2985 500000
    EVOLUS INC EOLS 2022-09-07 19:15:04 UTC 2.0215 0.2985 500000
    EVOLUS INC EOLS 2022-09-07 18:45:04 UTC 2.0152 0.3048 500000
    EVOLUS INC EOLS 2022-09-07 18:15:05 UTC 2.0152 0.3048 500000
    EVOLUS INC EOLS 2022-09-07 17:45:04 UTC 2.0152 0.3048 500000
    EVOLUS INC EOLS 2022-09-07 17:15:05 UTC 2.0152 0.3048 500000
    EVOLUS INC EOLS 2022-09-07 16:45:04 UTC 2.0032 0.3168 500000
    EVOLUS INC EOLS 2022-09-07 16:15:04 UTC 2.0032 0.3168 500000
    EVOLUS INC EOLS 2022-09-07 15:45:04 UTC 2.0032 0.3168 500000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund EOLS -9351.0 shares, $-104637.69 2022-04-30 N-PORT
    RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund EOLS -1789.0 shares, $-20752.4 2022-06-30 N-PORT

    Elevate your investments